The target action date for orforglipron is now April 10.

Eli Lilly’s new Pennsylvania build and why it matters for the stock Eli Lilly (LLY) has drawn fresh attention after outlining ...

Lilly CEO Dave Ricks is confident in the ability of the company's pill to compete and is preparing for a "full launch" in the second quarter.

Medicare's upcoming coverage of obesity treatments could dramatically expand access to Eli Lilly's (NYSE:LLY) experimental weight-loss pill, orforglipron, CEO Dave Ricks said Friday. Medicare Coverage ...

Eli Lilly (NYSE:LLY) shares edged 0.9% lower in premarket trading on Thursday after the U.S. Food and Drug Administration postponed its decision on the company’s weight-loss pill until April 10. The ...

According to the Centers for Disease Control and Prevention, 41.9 percent of U.S. adults were obese from 2017 to 2020.

Eli Lilly (LLY) shares slipped ~5% on Thursday, marking what could be its biggest intraday loss in five months after Reuters reported that a potential FDA nod for the company’s weight loss pill, ...

The long-held Wall Street expectation that the global market for obesity drugs would reach $150 billion in the next decade is ...

SAN FRANCISCO, Jan 12 (Reuters) - Eli Lilly's (LLY.N), opens new tab research and development head said on Monday the company will have plenty of supply to launch its much-anticipated new weight-loss ...

We’ve all heard of Ozempic by now. It’s only licensed for use as a diabetes treatment in the UK and US, but it's widely used ...

ALLENTOWN - In a big win for Pennsylvania and the Lehigh Valley, Eli Lilly & Co. has announced plans to build a $3.5 billion ...